TORONTO–( BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE AMERICAN:CYBN) (“Cybin” or the “Company”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that it has filed a new non-provisional patent application in support of its ongoing drug candidate programs. After what the company believes to be a favorable international search report of its May 2021 Patent…


Previous articleField Trip Health Ltd. Reports Fiscal First Quarter 2022 Financial Results
Next articlePT258 – Manesh Girn – Psychedelics and the Brain: Neuroplasticity and Creativity